Comparar compuestos
Seleccione hasta 3 compuestos para comparar protocolos, mecanismos, criterios de valoración y hallazgos de seguridad en paralelo.
Peptijournal · Survodutide · https://peptijournal.com/compare?c=survodutide · Impreso
Survodutide
Mismo objetivo
01Protocol
- Viales
- 10 / 20 mg
- Datos de dosis
- Referencia de laboratorio; no indicado
02Quick calculator
03Mechanism of action
Survodutide is a dual agonist of the glucagon and GLP-1 receptors, studied for weight and liver-fat effects.
04Study endpoints
- Phase 2 obesity trial (387 adults, 46 weeks): mean weight change of −6.2% to −14.9% across arms vs −2.8% with placebo.
- Phase 2 MASH trial: MASH improvement without worsening fibrosis in 43%–62% across arms vs 14% with placebo.
05Safety & regulatory findings
- Investigational: not approved by the FDA or EMA; phase 3 trials are ongoing.
- Adverse events were mainly gastrointestinal (75% vs 42% on placebo in the obesity trial); in the MASH trial nausea 66% vs 23% and vomiting 41% vs 4%.
06Citations
2 referencias · ver